Howard McLeod - 30 Mar 2022 Form 4 Insider Report for Vyant Bio, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 30 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Apr 2022, 16:30:34 UTC
Source filing: View source filing
Reporting owner signature: /s/ Andrew LaFrence, attorney-in-fact

Key filing fact

Howard McLeod filed Form 4 for Vyant Bio, Inc. on 01 Apr 2022.

Key facts

This page summarizes Howard McLeod's Form 4 filing for Vyant Bio, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Apr 2022, 16:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VYNT transaction

Common Stock, $0.0001 par value

Award

Transaction value
Shares: +43,478
Change %: +9683%
Price
Shares after: 43,927
Date: 30 Mar 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On March 30, 2022, the Reporting Person was granted 43,478 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on March 30, 2023, so long as Reporting Person remains a director though that date.